PURPOSE: To investigate the potential role of endothelin-1 (ET-1), a potent vasoconstrictor with mitogenic properties, in the pathogenesis of proliferative diabetic retinopathy (PDR). METHODS: Plasma and vitreous samples were collected from normal patients (controls; n = 25), diabetic patients with PDR (n = 25), and diabetic patients with non-PDR (n = 25). The patients had to have epiretinal membranes (ERMs) or other ocular conditions that made them candidates for vitrectomy. Immunoreactive ET-1 (IR-ET-1) was assayed in plasma and vitreous samples by radioimmunoassay. IR-ET-1 was immunohistochemically localized in ERMs. Expression of endothelin receptors A (ETA) and B (ETB) was confirmed by reverse transcription-polymerase chain reaction analysis. RESULTS: IR-ET-1 levels in plasma and vitreous samples from diabetic patients were higher (P < 0.0001) than those in samples from the control group. The levels for patients with PDR were even higher (P < 0.0001) than those for patients with non-PDR. Eyes with ERMs in the PDR group had the highest vitreous IR-ET-1 levels (14.67 +/- 0.67 pg/mL). IR-ET-1 was localized in the cellular and stromal components of ERMs in diabetic and nondiabetic patients. Furthermore, the ETA and ETB receptors were expressed in both diabetic and nondiabetic ERMs. CONCLUSIONS: Diabetic patients with PDR and ERMs had the highest plasma and vitreous IR-ET-1 levels. ET-1 and its ETA and ETB receptors were present in ERMs. These data suggest that ET-1 is involved in diabetic vitreoretinal disease.
PURPOSE: To investigate the potential role of endothelin-1 (ET-1), a potent vasoconstrictor with mitogenic properties, in the pathogenesis of proliferative diabetic retinopathy (PDR). METHODS: Plasma and vitreous samples were collected from normal patients (controls; n = 25), diabeticpatients with PDR (n = 25), and diabeticpatients with non-PDR (n = 25). The patients had to have epiretinal membranes (ERMs) or other ocular conditions that made them candidates for vitrectomy. Immunoreactive ET-1 (IR-ET-1) was assayed in plasma and vitreous samples by radioimmunoassay. IR-ET-1 was immunohistochemically localized in ERMs. Expression of endothelin receptors A (ETA) and B (ETB) was confirmed by reverse transcription-polymerase chain reaction analysis. RESULTS: IR-ET-1 levels in plasma and vitreous samples from diabeticpatients were higher (P < 0.0001) than those in samples from the control group. The levels for patients with PDR were even higher (P < 0.0001) than those for patients with non-PDR. Eyes with ERMs in the PDR group had the highest vitreous IR-ET-1 levels (14.67 +/- 0.67 pg/mL). IR-ET-1 was localized in the cellular and stromal components of ERMs in diabetic and nondiabeticpatients. Furthermore, the ETA and ETB receptors were expressed in both diabetic and nondiabetic ERMs. CONCLUSIONS:Diabeticpatients with PDR and ERMs had the highest plasma and vitreous IR-ET-1 levels. ET-1 and its ETA and ETB receptors were present in ERMs. These data suggest that ET-1 is involved in diabetic vitreoretinal disease.
Authors: L-A Khuu; F Tayyari; J M Sivak; J G Flanagan; S Singer; M H Brent; D Huang; O Tan; C Hudson Journal: Eye (Lond) Date: 2017-05-26 Impact factor: 3.775
Authors: Nicolette Binz; Elizabeth P Rakoczy; Ireni S Ali Rahman; Nermina N Vagaja; Chooi-May Lai Journal: PLoS One Date: 2016-08-02 Impact factor: 3.240
Authors: Patricia Bogdanov; Olga Simó-Servat; Joel Sampedro; Cristina Solà-Adell; Marta Garcia-Ramírez; Hugo Ramos; Marta Guerrero; Josep Maria Suñé-Negre; Josep Ramon Ticó; Bruno Montoro; Vicente Durán; Luís Arias; Cristina Hernández; Rafael Simó Journal: Int J Mol Sci Date: 2018-11-13 Impact factor: 5.923
Authors: Yen-Lin Chen; Yi Ren; Wenjuan Xu; Robert H Rosa; Lih Kuo; Travis W Hein Journal: Invest Ophthalmol Vis Sci Date: 2018-10-01 Impact factor: 4.799